Figure 1
The flow of biomaterial and associated clinical data of a sub-biobank for the Radboud Biobank.
Table 1
Overview of procedures on collection, processing and storage of samples defined in the Radboud Biobank biomaterial protocol.
| Sample | Volume/number | Processing | Time between sampling and storage | Aliquoting | Storage |
|---|---|---|---|---|---|
| DNA (blood) | 6 ml EDTA blood | Standard DNA isolation from EDTA in clinical routine of the Department of Human Genetics | Within 4 weeks (4°C) or 3 months (<–20°C) | Stock solution, after first issuance: normalized fraction 100 ng/μL | –20°C1 |
| Serum | 10 ml, addition of a clot activator | 2,000 × g at room temperature for 10 minutes | Within 2–4 hours | Maximum of six aliquots (0.5 ml) | –80°C2 |
| EDTA plasma | 10 ml | 2,000 × g at room temperature for 10 minutes | Within 2–4 hours | Maximum of six aliquots (0.5 ml) | –80°C2 |
| Heparin plasma | 10 ml | 2,000 × g at room temperature for 10 minutes | Within 2–4 hours | Maximum of six aliquots (0.5 ml) | –80°C2 |
| Citrate plasma | 9 ml | 2,000 × g at room temperature for 10 minutes | Within 2–4 hours | Maximum of six aliquots (0.5 ml) | –80°C2 |
| Cerebrospinal fluid (CSF) +/– cell count (CC) | 3–20 ml | 2,000 × g or 850 × g (CC) at 4°C or at room temperature (CC) for 10 minutes or 5 minutes (CC) | Within 2 hours | Maximum of six aliquots (0.5 ml) | –80°C2 |
| Urine | Not specified, midstream | 2,000 × g at 4°C for 10 minutes | Within 4 hours | Maximum of six aliquots (0.9 ml) | –80°C2 |
| Faeces | Not specified | Direct storage or after homogenization | Within 12 hours | Maximum of six aliquots (5 gram) | –80°C2 |
| Fresh frozen tissue | Sample of affected and unaffected tissue | Immediately frozen after collecting the sample | Immediate | 0.5 cm3 samples | –80°C2 |
| FFPE tissue3 | Sample of affected and unaffected tissue | Immediately stored in formalin after collecting the sample (0.5 cm3), afterwards embedded in paraffin | Immediate fixation | 0.5 cm3 samples | Room temperature |
[i] 1 –20°C in a fully automated storage system.
[ii] 2 –80°C in a manual storage system.
[iii] 3 FFPE = Formalin-Fixed Paraffin-Embedded.
Table 2
Disease-based biobanks included in the Radboud Biobank.
| Disease-based biobanks | Number of unique patients July 2017 – n = 32,587 (%) |
|---|---|
| Confirmed form/increased risk of colorectal cancer1 | 494 (1.5) |
| Cerebrovascular infarct/cerebral haemorrhage/venous thrombosis1 | 733 (2.5) |
| Rheumatoid arthritis and arthrosis2 [2] | 5,274 (16.2) |
| Neurodegenerative disorders (e.g. Alzheimer’s)1 | 124 (0.4) |
| Chronic (progressive) renal failure2 | 1,377 (4.2) |
| Crohn’s disease/ulcerative colitis1 | 382 (1.2) |
| Leukaemia, myeloma, lymphoma1 | 215 (0.7) |
| Type II diabetes1 | 400 (1.2) |
| Cerebrovascular vascular accident (18–50 years) | 570 (1.7) |
| Ischaemic heart disease1 | 162 (0.5) |
| Anomalies in children (e.g. malformations of the kidneys and urinary tract, intestines and anus, lip and palate, and the heart, childhood cancers; [3]) | 4,592 (14.1) |
| Parkinson’s disease | 1,230 (3.8) |
| Facioscapulohumeral muscular dystrophy (FSHD) | 233 (0.7) |
| Infantile facioscapulohumeral muscular dystrophy (iFSHD) | 45 (0.1) |
| Intellectual Disability | 639 (2.0) |
| Breast Cancer | 170 (0.5) |
| Asymptomatic women invited for breast cancer screening (50–75 years; [4]) | 5,674 (17.4) |
| Immune responses and microbiome [5] – Overweight patients (BMI>27) – Recurrent Vulvovaginal Candidiasis – HIV-infected patients – Type I diabetes – Healthy controls | 302 (0.9) 6 (<0.1) 216 (0.7) 176 (0.5) 535 (1.6) |
| Cancer – breast, prostate, bladder, kidney, ovarian, melanoma, lung, testis | 6,700 (20.7) |
| Autoinflammatory diseases | 21 (0.1) |
| Familial bladder cancer | 43 (0.1) |
| Myositis | 30 (0.1) |
| Endocrine diseases | 49 (0.2) |
| Urology | 1,312 (4.0) |
| Hereditary prostate cancer | 587 (1.8) |
| Congenital myopathy | 9 (<0.1) |
| Gynaecological oncology | 53 (0.2) |
| Systemic Sclerosis | 222 (0.7) |
| Rhabdomyolyse | 1 (<0.1) |
| Iron disorders [6] | 11 (<0.1) |
[i] 1 Parelsnoer Institute participant [1].
2 Both Parelsnoer Institute participant and department based biobank.
Table 3
Criteria used by the institutional review board to review applications for the use of biobank material and the accompanying clinical data.
|